Predictive Oncology Raises $545K Through Direct Stock Offering to Advance AI-Driven Drug Discovery Platform

Key Insights

• Predictive Oncology has successfully closed a registered direct offering of 363,336 shares at $1.50 per share, raising approximately $545,004 in gross proceeds for working capital and corporate purposes.
• The company's AI platform PEDAL demonstrates 92% accuracy in predicting tumor response to drug compounds, supported by a biobank of over 150,000 human tumor samples for comprehensive drug discovery solutions.
• H.C. Wainwright & Co. served as the exclusive placement agent for the offering, which was conducted under a previously declared effective SEC registration statement.

Predictive Oncology Inc. (NASDAQ: POAI), a pioneering force in AI-driven drug discovery and biologics, has successfully completed a registered direct offering, securing approximately $545,004 in gross proceeds. The transaction, announced and closed on February 19, 2025, involved the sale of 363,336 shares of common stock at $1.50 per share, priced at-the-market under Nasdaq rules.

Strategic Financing to Support AI-Driven Drug Discovery

The Pittsburgh-based company plans to utilize the net proceeds for working capital and general corporate purposes, strengthening its position in the competitive landscape of AI-powered drug development. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering, which was conducted under a "shelf" registration statement on Form S-3 that received SEC approval on May 21, 2024.

Advanced AI Platform Driving Oncology Innovation

At the heart of Predictive Oncology's operations is PEDAL, their scientifically validated artificial intelligence platform. This sophisticated system has demonstrated remarkable capabilities, achieving 92% accuracy in predicting tumor response to specific drug compounds. This predictive power significantly streamlines the drug discovery process by enabling more informed selection of drug-tumor type combinations for subsequent in-vitro testing.

Comprehensive Biobank Infrastructure

The company's technological advantages are further enhanced by its extensive biobank, containing more than 150,000 assay-capable heterogeneous human tumor samples. This vast collection, combined with their CLIA-certified laboratory facility, positions Predictive Oncology as a comprehensive solution provider for both academic institutions and industry partners in the drug discovery sector.

The offering was executed through a final prospectus supplement and accompanying prospectus filed with the SEC, with electronic copies available through the SEC's website and H.C. Wainwright & Co. The company has emphasized that this offering adheres to all applicable securities laws and regulations, ensuring compliance across jurisdictions.